Baidu
map

Hypertension:当下慢性肾脏病患儿的血压控制的是否达标?

2018-01-04 MedSci MedSci原创

慢性肾脏病(CKD)患儿血压控制不良被认为是CKD进展的主要原因,同时会增加心血管疾病的风险。近期,有推荐更好的控制血压(BP)的方法。本文主要目的是对比CKiD研究(儿童慢性肾脏病)中的受试者在两个时间段血压控制情况。对两个时间段(2005年1月1日-2008年7月1日[1期,345人]和2010年7月1日-2013年12月31日[2期,506人])的851位受试者的抽检BP和24小时动态BP数

慢性肾脏病(CKD)患儿血压控制不良被认为是CKD进展的主要原因,同时会增加心血管疾病的风险。近期,有推荐更好的控制血压(BP)的方法。本文主要目的是对比CKiD研究(儿童慢性肾脏病)中的受试者在两个时间段血压控制情况。

对两个时间段(2005年1月1日-2008年7月1日[1期,345人]和2010年7月1日-2013年12月31日[2期,506人])的851位受试者的抽检BP和24小时动态BP数据进行对比。用合适的统计学方式处理数据,并根据混杂因素校正。

两个时间段的抽检血压状态无显着差异(高血压前期:15% vs 15%;未控高血压:18% vs 17%;p=0.87)。对动态BP数据的分析显示,2期动态BP指数更高,多见隐匿性高血压(36% vs 49%;p<0.001)。2期的平均睡眠BP指数(p<0.05)和睡眠BP负荷(p<0.05)均更高。

综上所述,尽管有已发表的针对CKD患者的控制血压的指南,但对于CKD患儿,高血压仍未得到良好的控制,而且公众认识度也不足。此外,本文同时强调了常规动态监测血压对CKD患儿的重要性。

原始出处:

Gina-Marie Barletta,et al.Is Blood Pressure Improving in Children With Chronic Kidney Disease?Hypertension.January2, 2017;https://doi.org/10.1161/HYPERTENSIONAHA.117.09649

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2038810, encodeId=9cf1203881097, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Tue Nov 20 05:58:00 CST 2018, time=2018-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726981, encodeId=2a851e26981f0, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Sep 05 15:58:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277895, encodeId=3b792e7895b4, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Fri Jan 12 19:26:14 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446297, encodeId=b318144629e40, content=<a href='/topic/show?id=875e88946d1' target=_blank style='color:#2F92EE;'>#血压控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88946, encryptionId=875e88946d1, topicName=血压控制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28a45200046, createdName=gj0733, createdTime=Sat Jan 06 13:58:00 CST 2018, time=2018-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501244, encodeId=e8dd15012446f, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Sat Jan 06 13:58:00 CST 2018, time=2018-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1616138, encodeId=c84b1616138e1, content=<a href='/topic/show?id=9c95536521c' target=_blank style='color:#2F92EE;'>#慢性肾脏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53652, encryptionId=9c95536521c, topicName=慢性肾脏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=305019728622, createdName=12498b08m96暂无昵称, createdTime=Sat Jan 06 13:58:00 CST 2018, time=2018-01-06, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2038810, encodeId=9cf1203881097, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Tue Nov 20 05:58:00 CST 2018, time=2018-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726981, encodeId=2a851e26981f0, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Sep 05 15:58:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277895, encodeId=3b792e7895b4, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Fri Jan 12 19:26:14 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446297, encodeId=b318144629e40, content=<a href='/topic/show?id=875e88946d1' target=_blank style='color:#2F92EE;'>#血压控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88946, encryptionId=875e88946d1, topicName=血压控制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28a45200046, createdName=gj0733, createdTime=Sat Jan 06 13:58:00 CST 2018, time=2018-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501244, encodeId=e8dd15012446f, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Sat Jan 06 13:58:00 CST 2018, time=2018-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1616138, encodeId=c84b1616138e1, content=<a href='/topic/show?id=9c95536521c' target=_blank style='color:#2F92EE;'>#慢性肾脏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53652, encryptionId=9c95536521c, topicName=慢性肾脏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=305019728622, createdName=12498b08m96暂无昵称, createdTime=Sat Jan 06 13:58:00 CST 2018, time=2018-01-06, status=1, ipAttribution=)]
    2018-09-05 feather89
  3. [GetPortalCommentsPageByObjectIdResponse(id=2038810, encodeId=9cf1203881097, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Tue Nov 20 05:58:00 CST 2018, time=2018-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726981, encodeId=2a851e26981f0, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Sep 05 15:58:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277895, encodeId=3b792e7895b4, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Fri Jan 12 19:26:14 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446297, encodeId=b318144629e40, content=<a href='/topic/show?id=875e88946d1' target=_blank style='color:#2F92EE;'>#血压控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88946, encryptionId=875e88946d1, topicName=血压控制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28a45200046, createdName=gj0733, createdTime=Sat Jan 06 13:58:00 CST 2018, time=2018-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501244, encodeId=e8dd15012446f, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Sat Jan 06 13:58:00 CST 2018, time=2018-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1616138, encodeId=c84b1616138e1, content=<a href='/topic/show?id=9c95536521c' target=_blank style='color:#2F92EE;'>#慢性肾脏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53652, encryptionId=9c95536521c, topicName=慢性肾脏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=305019728622, createdName=12498b08m96暂无昵称, createdTime=Sat Jan 06 13:58:00 CST 2018, time=2018-01-06, status=1, ipAttribution=)]
    2018-01-12 虈亣靌

    谢谢分享.学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2038810, encodeId=9cf1203881097, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Tue Nov 20 05:58:00 CST 2018, time=2018-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726981, encodeId=2a851e26981f0, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Sep 05 15:58:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277895, encodeId=3b792e7895b4, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Fri Jan 12 19:26:14 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446297, encodeId=b318144629e40, content=<a href='/topic/show?id=875e88946d1' target=_blank style='color:#2F92EE;'>#血压控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88946, encryptionId=875e88946d1, topicName=血压控制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28a45200046, createdName=gj0733, createdTime=Sat Jan 06 13:58:00 CST 2018, time=2018-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501244, encodeId=e8dd15012446f, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Sat Jan 06 13:58:00 CST 2018, time=2018-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1616138, encodeId=c84b1616138e1, content=<a href='/topic/show?id=9c95536521c' target=_blank style='color:#2F92EE;'>#慢性肾脏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53652, encryptionId=9c95536521c, topicName=慢性肾脏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=305019728622, createdName=12498b08m96暂无昵称, createdTime=Sat Jan 06 13:58:00 CST 2018, time=2018-01-06, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2038810, encodeId=9cf1203881097, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Tue Nov 20 05:58:00 CST 2018, time=2018-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726981, encodeId=2a851e26981f0, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Sep 05 15:58:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277895, encodeId=3b792e7895b4, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Fri Jan 12 19:26:14 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446297, encodeId=b318144629e40, content=<a href='/topic/show?id=875e88946d1' target=_blank style='color:#2F92EE;'>#血压控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88946, encryptionId=875e88946d1, topicName=血压控制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28a45200046, createdName=gj0733, createdTime=Sat Jan 06 13:58:00 CST 2018, time=2018-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501244, encodeId=e8dd15012446f, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Sat Jan 06 13:58:00 CST 2018, time=2018-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1616138, encodeId=c84b1616138e1, content=<a href='/topic/show?id=9c95536521c' target=_blank style='color:#2F92EE;'>#慢性肾脏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53652, encryptionId=9c95536521c, topicName=慢性肾脏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=305019728622, createdName=12498b08m96暂无昵称, createdTime=Sat Jan 06 13:58:00 CST 2018, time=2018-01-06, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2038810, encodeId=9cf1203881097, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Tue Nov 20 05:58:00 CST 2018, time=2018-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726981, encodeId=2a851e26981f0, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Sep 05 15:58:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277895, encodeId=3b792e7895b4, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Fri Jan 12 19:26:14 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446297, encodeId=b318144629e40, content=<a href='/topic/show?id=875e88946d1' target=_blank style='color:#2F92EE;'>#血压控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88946, encryptionId=875e88946d1, topicName=血压控制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28a45200046, createdName=gj0733, createdTime=Sat Jan 06 13:58:00 CST 2018, time=2018-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501244, encodeId=e8dd15012446f, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Sat Jan 06 13:58:00 CST 2018, time=2018-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1616138, encodeId=c84b1616138e1, content=<a href='/topic/show?id=9c95536521c' target=_blank style='color:#2F92EE;'>#慢性肾脏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53652, encryptionId=9c95536521c, topicName=慢性肾脏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=305019728622, createdName=12498b08m96暂无昵称, createdTime=Sat Jan 06 13:58:00 CST 2018, time=2018-01-06, status=1, ipAttribution=)]

相关资讯

Hepatology:慢性丙型肝炎增加慢性肾脏病的风险!

近期,一项发表在杂志Hepatology上的研究旨在评估慢性丙型肝炎病毒(HCV)感染患者发生慢性肾脏疾病(CKD)的风险,以及接受HCV治疗后CKD发生率的降低情况。此外,还评估了慢性HCV患者膜增生性肾小球肾炎(MPGN)和冷球蛋白血症的风险。研究者们对美国Truven Health MarketScan数据库(2008-2015)进行了回顾性队列分析。在56,448例HCV感染患者和倾向评分

Chin Med J:尿液生物标志物或可用于慢性肾脏病的诊断

在即将到来的精准医学时代,寻求早期的非侵入性生物标志物一直是慢性肾脏病(CKD)治疗的基石和主要挑战。尿液含有丰富的生物学信息,可作为CKD非侵入性生物标志物的理想来源。本次回顾将讨论尿液生物标志物的最新进展。研究人员检索2017年6月20日之前在PubMed数据库中发表的文章,其中包含以下关键词:“慢性肾脏疾病”,“生物标记物”和“尿液”。纳入关于尿液生物标志物的原始研究及综述进行审查。结果显示

Crit Care:ICU中AKI患者开始肾脏替代治疗的时机和慢性肾脏病的长期风险如何?

由此可见,早期接受RRT治疗与90天死亡率增加有关。在存活了90天的患者中,早期接受治疗与长期死亡率或CKD和ESRD风险无关。尽管观察设计可能导致潜在的混杂因素,但该研究的结果并不支持早期RRT治疗优于晚期RRT。

Kidney int:慢性肾脏疾病与心血管死亡风险的相关性研究!

在实验性尿毒症中的研究发现了微血管稀少的现象,但是,关于慢性肾脏病(CKD)患者的相关研究数据十分有限。基于此,近期,一项发表在杂志Kidney int上的研究量化了在单个机构的心肌灌注正电子发射断层扫描的绝对心肌血流量和冠状动脉血流储备情况(峰值与静息流量的比率)。研究者们根据估计的肾小球滤过率,将受试个体分为标准CKD类别。在心血管危险因素调整模型中分析了冠状动脉血流储备与CKD分期和心血管死

慢性肾脏病患者妊娠管理指南

随着医学的进步,慢性肾脏病(CKD)女性患者妊娠率较前升高,总体胎儿活产率明显增加。但是,CKD患者妊娠仍存在较大的风险:孕妇不良结局包括原有的肾脏损害加重、发生急性肾损伤和奸娠相关肾脏病、蛋自尿增加、血压升高、并发子痛前期(PE)等;胎儿不良结局包括死胎、胎儿生长受限(FGR)和早产等。随着国家全面放开二胎政策,CKD患者妊娠问题日益成为肾脏科及产科医师共同面临的挑战。因此,为了减少奸娠对母体肾

2017 KDIGO 临床实践指南更新:慢性肾脏病矿物质与骨异常诊断、评估、预防和治疗

2017 年更新版指南的制订,基于严格的证据审查和评估,根据临床试验结果进行系统综述,采用GRADE 评分系统评判每条推荐的证据级别,并在适当的情况下工作组依据一般性意见制订“证据未分级”的建议。尽管在某些CKD-MBD 研究领域尚缺乏高质量证据,工作组仍致力于制订出对肾脏病学界具有高价值的指导性综合性指南,帮助医师更好地管理和治疗成人及儿童慢性肾脏病、维持透析或肾移植患者,并为未来的研究提供方向

Baidu
map
Baidu
map
Baidu
map